Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

NovaMed Raises $14 Million to In-license New Molecules

publication date: Jan 22, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NovaMed Pharmaceuticals Inc., a CRO and out-sourced distribution company based in Shanghai, announced that it has closed a Series B funding round worth $13.8 million. In May 2007, the company raised $5 million in an A round. NovaMed was founded in 2005. NovaMed said that it would use the money to in-license new molecules to develop in China, expand its sales/distribution organization and build up its R&D capacity. More details...

Stock Symbols: (NYSE: WX) (NYSE: SNY) (NYSE: BAX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners